SUMMIT trial primary endpoint: cardiovascular death or worsening heart failure. Tirzepatide 9.9% vs. placebo 15.3%, HR 0.62 (95% CI 0.41–0.95), p=0.026. Source: Packer M…
Read articleExponential decay curve: tirzepatide plasma concentration (% of peak) vs. days post-injection. The ~5-day half-life midpoint and Day 7 next-dose marker (37% remaining) are…
Read articleLegal Status as of June 2026: The FDA removed tirzepatide from its drug shortage list on December 19, 2024. Mass-market 503A and 503B compounding…
Read articleMedical review notice: This article provides general educational information about tirzepatide’s interaction profile. It does not replace individualized medical advice from your prescriber or…
Read articleThis content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any…
Read articleMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider about which tirzepatide indication…
Read articleThis content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before adjusting your dose, stopping tirzepatide,…
Read articleJump to section:Is Hair Loss a Real Side Effect? · The Telogen Effluvium Mechanism · What the Clinical Trials Show · Timeline · Nutritional…
Read articleApproved tirzepatide subcutaneous injection zones. All three sites — abdomen, upper outer thigh, and posterior upper arm — are validated by the FDA-labeled prescribing…
Read articleFigure 1: Gastric emptying under tirzepatide versus normal — showing why alcohol exposure is prolonged in the stomach, amplifying both GI side effects and…
Read articleHero flat-lay photograph showing a well-composed tirzepatide-friendly meal spread: grilled salmon, Greek yogurt, steamed vegetables, whole grain toast, fresh berries, and a glass of…
Read articleMedical & Legal Disclaimer: This article provides regulatory and legal information for educational purposes only. It does not constitute legal or medical advice. Regulatory…
Read articleMedical & Legal Disclaimer: This article discusses compounded tirzepatide, including products that are no longer legally available in most circumstances due to FDA regulatory…
Read articleMedical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individual eligibility for tirzepatide depends on a clinical evaluation…
Read articleHorizontal Gantt-style bar chart titled “Tirzepatide Patent Protection Timeline (2022–2041)” showing four colored bars: FDA Approval/NCE Exclusivity (2022–2027, dark blue), Composition of Matter… The…
Read articleConceptual diagram of tirzepatide’s 39-amino-acid peptide structure with C20 fatty diacid moiety annotated — peptide backbone in blue, fatty moiety in teal/amber, albumin binding…
Read articleBar chart comparing tirzepatide mean percent body weight loss across SURMOUNT-1 dose groups (5 mg −15.0%, 10 mg −19.5%, 15 mg −20.9%), SURMOUNT-5 tirzepatide…
Read articleSide-by-side diagram comparing tirzepatide dual GIP+GLP-1 receptor agonism versus semaglutide single GLP-1 receptor agonism, with arrows showing downstream metabolic effects for each pathway Tirzepatide…
Read articleGrouped horizontal bar chart comparing tirzepatide GI side effect rates (nausea, diarrhea, vomiting, constipation) in T2D trials (SURPASS) vs Introduction Gastrointestinal side effects are…
Read articleStep-line chart showing tirzepatide dose escalation from 2.5 mg to 15 mg over 20+ weeks, with each dose tier labeled by week range and…
Read article